Alvotech Secures EMA Nod for AVT06 and Raises SEK 750M Ahead of FDA Verdict
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Alvotech (NASDAQ: ALVO) is a biotechnology company headquartered in Reykjavík, Iceland, specializing in the development and manufacture of biosimilar medicines. Founded in 2013, the company utilizes a vertically integrated model—from cell line development through fill-and-finish manufacturing—to provide cost-competitive biologic therapies to patients globally.
Corporate Structure
Alvotech employs between 501 and 1,000 individuals, including scientists, quality assurance specialists, and manufacturing personnel. In July 2025, Linda Jónsdóttir was appointed Chief Financial Officer, bringing experience from banking, healthcare, and food technology. The company has established commercial partnerships across North America, Europe, and Asia, collaborating with Teva Pharmaceuticals, Advanz Pharma, Dr. Reddy’s Laboratories, among others, to enhance global distribution.
Biosimilar medicines by little plant
Recent Developments and News
- February 18, 2025: The U.S. Food and Drug Administration accepted for review Alvotech’s Biologics License Application for AVT06, a proposed biosimilar to Eylea® (aflibercept), with a target completion in Q4 2025.
- June 4, 2025: A private placement raised gross proceeds of SEK 750 million, aimed at funding research and development and manufacturing expansion.
- July 28, 2025: Filing of an automatic shelf registration statement (Form F-3ASR) to facilitate future offerings of equity, debt securities, and warrants.
- August 13, 2025: Submission of a Form 6-K covering June 30 half-year results, indicating revenue growth, improved net income, and continued investment in research and development.
- August 20, 2025: Appointment of Patrik Ling as Vice President of Investor Relations for Scandinavia.
- August 21, 2025: European Medicines Agency approval was granted to Mynzepli®, the AVT06 biosimilar to Eylea®, in collaboration with Advanz Pharma.
Financial and Strategic Analysis
As of August 25, 2025, Alvotech’s share price was $8.4592, reflecting a 0.11% increase for the day. Trading volume reached 388,835 shares compared to a 224-share average. Key financial metrics include:
| Metric | Value |
|---|---|
| Market Capitalization | $2.63 billion |
| Trailing P/E (TTM) | 36.74 |
| Revenue (TTM) | $562.5 million |
| Net Income (TTM) | $63.4 million |
| Total Cash (mrq) | $151.5 million |
| Levered Free Cash Flow | –$164.7 million |
Alvotech’s strategy includes a diverse pipeline of biosimilars targeting therapeutics in immunology, ophthalmology, oncology, and bone disease. Collaborations with Teva and others support commercialization efforts, while the Form F-3ASR shelf registration enables capital-raising flexibility. Investment in research and development constitutes a significant portion of operating expenses, facilitating clinical trials and regulatory filings.
Market Position and Industry Context
In the global biosimilars landscape, Alvotech competes with established pharmaceutical companies and emerging biotechnology firms. The company's vertically integrated manufacturing platform is designed to deliver potential advantages in cost and production cycle times. The current pipeline includes approved biosimilars for Humira® (adalimumab) and Stelara® (ustekinumab) in multiple markets, as well as AVT06 and several additional candidates in various stages of development. Achieving regulatory approvals and ensuring supply chain resilience are critical as the adoption of biosimilars expands.
tl;dr
On August 13, 2025, Alvotech reported increased revenue and net income for the first half of 2025, supported by ongoing investments in research and development. The FDA accepted its Biologics License Application for AVT06 on February 18, 2025, with a decision expected in Q4 2025, while the EMA approved Mynzepli® on August 21, 2025. A SEK 750 million private placement on June 4 and an F-3ASR shelf registration on July 28, 2025, position Alvotech for future financing. Trading volume reached 388,835 shares on August 25, indicating market interest ahead of forthcoming regulatory milestones.